EMR
NYSE
Emerson Electric Co.
What happened
-6.20%
2026-03-05
From 2026-03-05 session.
Drops sharply despite beating Q1 estimates; margin compression and weak cash flow spook investors
Emerson Electric reported first quarter 2026 results on February 3, 2026. Net sales increased 4 percent to 4.346 billion dollars, with underlying sales growth of 2 percent. The company delivered adjusted earnings per share of 1.46 dollars, up 6 percent year-over-year.
Full analysis covers our editorial take, sources, and more.
EMR explained
What does Emerson Electric Co. do?
Emerson Electric is a St. Louis-based global automation leader that provides intelligent devices, control systems, and industrial software to optimize operations across process industries. The company completed its transformation into a pure-play automation business through the AspenTech integration and Test & Measurement divestiture. Today's selloff appears tied to lingering concerns over margin compression and cash flow deterioration reported in its fiscal Q1 results.
How does WTF Just Happened track Emerson Electric Co.?
We watch EMR for moves that stand out from normal trading -- the kind of day that makes you ask "WTF just happened?" When Emerson Electric Co. moves beyond its usual range, our AI digs through 15-20 news sources to piece together what drove it. No predictions, no trading advice -- just a clear explanation in about 30 seconds.
What a WTF analysis looks like
From a recent analysis
The near-zero move marks the first session without meaningful downside since the CagriSema trial results triggered a 16% single-day collapse on Monday. The cumulative decline over five sessions exceeds 20%, and today's stabilization — particularly against a weak broader market tape — suggests the acute phase of post-trial repositioning has run its course. the stock is underperforming pharma peers by about 0.8 percentage points, a far narrower gap than the 2-3 point divergences seen earlier in the week, indicating the stock-specific pressure is fading. No fresh catalysts have emerged since Tuesday's U.S. price-cut announcement and JP Morgan downgrade. The Kepler Capital Markets downgrade to Hold reported Wednesday is reactive to the prior week's events rather than a new development. Consensus now sits at Hold with an average price target of $56.07, roughly 49% above current levels — a wide gap that reflects deep uncertainty about Novo's competitive trajectory rather than conviction in near-term upside.